Eurofins Genomics Adds NGS to ISO17025 Accredited Testing Portfolio|
Saturday, August 16, 2014
ISO17025 accreditation to consistently offer valid results for testing in the fields of veterinary medicine, pharmaceuticals, food and animal feed, commodities and health care.
BD BACTEC FX40 Blood Culture Instrument Now Communicates with the BD EpiCenter Data Management System
Saturday, June 14, 2014
Low-Volume Clinical Laboratories Now Have Access to Advanced Data Management with New Blood Culture Instrument Connectivity
New MCO-170AIC CO2 incubator from Panasonic demonstrates exceptional control and optimises cell culture productivity
Monday, June 09, 2014
New MCO-170AIC CO2 incubators from Panasonic deliver outstanding quality in performance, maximise cell culture efficiency and provide optimum results and reproducibility. Designed specifically for the safe, consistent cultivation of successful cell lines, this latest innovation offers the very highest levels of precision, security and ease of use.
Nanobiotix Presents Successful Phase I Results for NBTXR3 at ASCO
Tuesday, June 03, 2014
Final results demonstrate a very good safety, treatment feasibility and promising signs of efficacy in patients with advanced Soft Tissue Sarcomas.
Debiopharm Moves Forward Three of its Oncology Clinical Programs
Thursday, May 29, 2014
Company will present the recent progresses at the 50th American Society of Clinical Oncology Annual Meeting.
Completion or Enrollment in the Phase III Confirmatory Study of KIACTA™
Thursday, May 29, 2014
KIACTA™ Phase III Confirmatory Study expected to be completed in 2016.
Sciformix to Reveal Strategic Model for Talent Acquisition at the DIA 50th Annual Meeting
Thursday, May 22, 2014
New career strategy aims to address talent acquisition and retention requirements for capacity expansion.
Aptiv Solutions Improves Accuracy of Dose Escalation Studies with Launch of ADDPLAN® DF 3.0
Friday, May 16, 2014
ADDPLAN® DF 3.0 incorporates complex statistical methodologies to prevent under and over-estimation of a therapeutic’s maximum target dose (MTD) during Phase I dose escalation trials.
Da Volterra's DAV132 Shown As Promising Candidate for Preventing Severe C. Difficile Infections
Tuesday, May 13, 2014
The CL1001 clinical trial also demonstrated the adequate targeted delivery of DAV132 to the ileum and the colon and its adsorbing effects.